Refine by
Breast Tissue Articles & Analysis
27 news found
Tamoxifen Citrate Tamoxifen Citrate is a medication used to treat breast cancer and prevent its recurrence. It works by blocking the effects of estrogen on breast tissue, which can promote the growth of cancer cells. ...
Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. ...
The results evaluating the association of DCISionRT, a predictive DCIS Biosignature to assess the impact of Endocrine Therapy (ET) on 10-year ipsilateral breast recurrence (IBR) risk after breast conserving surgery alone or with radiation therapy (RT), will be presented on June 7, 2022 at McCormick Place, Chicago, IL. ...
We now understand that traditional clinicopathologic features alone are ineffective and potentially lead to over-or under-treatment of DCIS,” said Pat Whitworth, MD, FACS, Principal Investigator and Breast Surgical Oncologist Director, Nashville Breast Center; Managing Partner TME. ...
Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. ...
“Traditional clinicopathologic features fail to stratify patients appropriately,” said Pat Whitworth, MD, FACS, Principal Investigator and Breast Surgical Oncologist Director, Nashville Breast Center; Managing Partner TME. ...
Reveal Surgical is working on changing that reality through its new, AI-based Sentry technology, which leverages a combination of AI and Raman spectroscopy to provide real-time tissue diagnostics during surgery for otherwise-invisible tumors. Raman spectroscopy is the use of light scattering from a laser to detect molecular structures and compositions of a material—in this ...
The company recently finished their first Republic crowdfunding campaign, exceeding capital targets, and raising over $2.6M in only 5 months. Koning's FDA breast screening trial is also underway with participating clinics in Daytona Beach, FL and Knoxville, TN. ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced the publication of SweDCIS randomized clinical trial data in the Special Issue: Updates on Breast Cancer edition of Cancers. ...
Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. ...
We are proud to be the only no-compression, true 3D breast imaging device manufacturer that already has FDA diagnostic approval; this screening trial gives us even more momentum in our push to improve breast health for all women." ...
QView Medical is the only FDA AI Ultrasound Technology approved for breast screening. But now, we are moving beyond the clinical suite. QView is joining women in the initiative around Breast Cancer with the launch of AmIDense.com and the supporting #AmIDense. Let's START the conversation around Breast Density. The 2021 American Cancer Society's ...
This is the start of exponential growth for Koning, as well as a major step forward in the pursuit of bringing women’s breast health into the future.” Why This Matters 80% of the Asian female population have dense breasts. This makes it harder for conventional mammograms to find lesions, especially at their earliest stages. Koning ...
“It goes to show how excited people are about our mission and demonstrates people’s desire to help millions of women around the world avoid later-stage breast cancer diagnoses.” The company aims to raise a maximum of $5M via Republic. ...
Of over 100 applicants, Koning is one of only ten companies that has been chosen and will showcase the Koning Breast CT - a technology that will change millions of women’s lives around the world through no compression, low dose, and true 3D imaging. ...
“After working through the worst of the pandemic in 2020, we’re re-energized and ready to bring no-compression breast exams to women everywhere.” Koning Milestones Breast CT received dedicated reimbursement codes in the US in March and clinics running exams with the Koning Breast CT (KBCT) have been billing to those codes ...
Current breast imaging modalities fall significantly short in being able to identify lesions; about 35% of breast cancers are missed by traditional mammography, and that number goes up to 70% for women with dense breasts. ...
Current breast imaging modalities fall significantly short in being able to identify lesions; about 35% of breast cancers are missed by traditional mammography, and that number goes up to 70% for women with dense breasts. ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that its study in 926 patients demonstrating the clinical utility of DCISionRT and its Residual Risk Subtype (RRt) was selected for a scientific session oral presentation at the American Society of Breast Surgeons (ASBrS) 23rd ...
The AMA technical subcommittee, comprised of prominent members of the American College of Radiology (ACR) assigned to evaluate the merit of the new technology unanimously advocated for the 6 dedicated CT codes for breast CT which further validates this advance in breast imaging. CPT codes allow providers to bill towards insurance payors for AMA recognized ...